Protein Linked to Colorectal Cancer Spread
A newly identified protein may fuel tumor growth, potentially offering a future target for immunotherapy research.
Updated on Oct. 15, 2026 in Cancer
Researchers have identified that the protein SRPX2 drives metastasis in colorectal cancer by stabilizing a key signaling receptor. This finding highlights a potential new therapeutic target for aggressive cancer subsets that are currently resistant to immunotherapy.
Why it matters
Identifying SRPX2 as a key player in tumor progression offers a path toward overcoming immunotherapy resistance in metastatic colorectal cancer. By focusing on this specific signaling axis, future treatments may be able to better manage aggressive disease states.
A preclinical study in tumor models demonstrates that SRPX2 ablation suppresses liver metastasis. While SRPX2 is linked to immunotherapy resistance, clinical translation of these findings has not yet been investigated.
The details
The protein SRPX2 functions by binding to and stabilizing the TGFBR2 receptor, which effectively switches on the TGF-beta signaling pathway. This activation promotes epithelial-mesenchymal transition and extracellular matrix remodeling, processes that help cancer cells spread and resist immune responses. Targeting this specific axis is being explored as a method to improve patient response to checkpoint inhibitor therapies.
Timeline
October 15, 2026: The research findings were published.
Health Landscape
The TGF-beta signaling pathway is a primary target in current oncology research due to its role in tumor immune evasion. By pinpointing SRPX2, researchers are narrowing the field of potential treatments for aggressive colorectal cancer.
This study is preclinical and does not yet change current treatment standards or clinical recommendations for patients. Those with metastatic colorectal cancer should discuss all available immunotherapy options and clinical trial opportunities with their oncology team.
The takeaway
SRPX2 acts as a catalyst for colorectal cancer metastasis and treatment resistance. Patients should focus on maintaining open communication with their oncologist regarding the most appropriate care plans for their specific cancer profile.
Further reading
Learn more about the latest research and standard treatment options for Cancer.
More information
Read the full results in the peer-reviewed research article.
Source note: This article includes information reported by Nature.
